ArticlemAbs2015

Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.

Chien-Hsing Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.